From: The MATE trial: a multicentre, mixed-methodology, pilot, randomised controlled trial in neovascular age-related macular degeneration
Main MATE trial
Treatment arm A: SC
Treatment arm B: T&E
Mean age (years; SD)
78.98 (7.7)
78.4 (6.5)
Gender
 Female (%)
11 (55%)
 Male (%)
9 (45%)
BCVA (SD)
60.8 (12.5)
63.7 (10.0)
CRT (µm; SD)
414.3 (144.5)
406.6 (114.6)